November 24, 2022
WPD Pharmaceuticals terminates grant agreement with the NCRD for the POIR.01.01.01-00-2382/20-00 project; resignation from the WPD’s Board of Directors
November 18, 2022
WPD Pharmaceuticals Provides a Corporate Update
May 16, 2022
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
February 3, 2022
WPD Pharmaceuticals Announces Appointment of New Director
July 2, 2021
Request for bids No 01/WPD108/2021
July 2, 2021
Zapytanie ofertowe nr 01/WPD108/2021
WPD Pharmaceuticals Provides a Corporate Update
December 16, 2021
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML
October 1, 2021
WPD Pharmaceuticals Announces AGSM Results
June 28, 2021
WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021
May 11, 2021
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
April 29, 2021
WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
March 30, 2021
WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates
March 16, 2021
WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101
February 24, 2021
WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials
February 11, 2021
WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Further Support on Berubicin Trials
February 9, 2021
WPD Pharmaceuticals Announces US$1.5M Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin
February 5, 2021
WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug
January 28, 2021
WPD Pharmaceuticals to Participate in the 7th Annual LSX World Congress, a Leading Global Healthcare and Life Sciences Forum
October 26, 2020
WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada
October 15, 2020
WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials
September 16, 2020
WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101
September 9, 2020
WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials
September 1, 2020
WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate
August 17, 2020
WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO
July 23, 2020
WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
July 3, 2020
WPD Pharmaceuticals OTC Symbol Change to WPDPF
May 28, 2020
WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate
May 15, 2020
WPD Pharmaceuticals To Resume Trading
May 5, 2020
WPD Pharmaceuticals Comments on SEC Order
April 30, 2020
WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
April 23, 2020
WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity
April 21, 2020
WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
April 16, 2020
WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate
April 9, 2020
WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%
April 8, 2020
WPD Pharmaceuticals Provides Corporate Update
March 24, 2020
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
March 19, 2020
WPD Pharmaceuticals’ WP1122 Drug to Be Tested on a Range of Viruses Including Coronavirus
March 13, 2020
WPD Pharmaceuticals Announces Brain Cancer Patient From Berubicin Phase 1 Trial Remains Cancer Free
March 11, 2020
WPD Pharmaceuticals Received $800,000 Reimbursement From $7.4 Million Government Grant for Development of Glioblastoma Drug
February 27, 2020
WPD Pharmaceuticals’ Annamycin Received Positive Interim Results from Phase 1/2 Clinical Studies in Acute Myeloid Leukemia
February 24, 2020
WPD Pharmaceuticals Granted Key Patent Exclusively Licensed From Wake Forest University
February 20, 2020
WPD Pharmaceuticals' Stat3 Inhibitor Received FDA Approval of Ind Status in Pediatric Brain Cancer Trial
February 18, 2020
WPD Pharmaceuticals’ Wp1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials
February 12, 2020
WPD Pharmaceuticals to Conduct Clinical Trials in Pediatric Brain Tumors Through Collaboration with Cns Pharmaceuticals
February 10, 2020
WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery
February 5, 2020
WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation
January 31, 2020
WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates
January 8, 2020
WPD Pharmaceuticals Provides 2019 Corporate Year End Review
December 21, 2018
WESTCOT ANNOUNCES CHANGE OF AUDITOR
August 28, 2018
WESTCOT CLOSES PRIVATE PLACEMENTS TO RAISE UP TO $2,764,998.60 AND ENTERS INTO SHARE EXCHANGE AGREEMENT
July 27, 2018
WESTCOT ANNOUNCES PRIVATE PLACEMENTS TO RAISE UP TO $3,100,000 AND PROVIDES CORPORATE UPDATE
July 19, 2018
WESTCOT ANNOUNCES AGM RESULTS
July 10, 2018
WESTCOT PROPOSES 2:1 FORWARD SPLIT
November 21, 2017
WESTCOT CLOSES PRIVATE PLACEMENT AND ANNOUNCES MANAGEMENT CHANGES
October 18, 2017
WESTCOT ANNOUNCES PRIVATE PLACEMENT
October 10, 2017
WESTCOT REPORTS DEBENTURES CONVERSION
September 18, 2017
WESTCOT ANNOUNCES CHANGE OF TRADING SYMBOL
September 14, 2017
SPARROW ANNOUNCES REINSTATEMENT TO TRADING, CONSOLIDATION, AND NAME CHANGE TO WESTCOT VENTURES CORP.
August 11, 2017
SPARROW ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER
June 23, 2017
SPARROW CLOSES FINAL TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING AND APPOINTS DIRECTOR
February 8, 2017
SPARROW ANNOUNCES REVOCATION OF CEASE TRADE ORDERS
October 31, 2016
SPARROW ANNOUNCES NEW DIRECTOR APPOINTMENT
October 3, 2016
SPARROW ANNOUNCES FIRST CLOSING OF SECURED CONVERTIBLE DEBENTURES OFFERING AND APPOINTS DIRECTOR
August 18, 2016
SPARROW ANNOUNCES PARTIAL REVOCATION OF CEASE TRADE ORDER
August 24, 2015
SPARROW ANNOUNCES RESIGNATION OF DIRECTOR
June 25, 2015
SPARROW ANNOUNCES RESIGNATION OF CFO
June 17, 2014
SPARROW ANNOUNCES GRANT OF OPTIONS
June 16, 2014
TRANSFER OF LISTING TO NEX
June 4, 2014
Sparrow Announces Unsecured Loan
January 20, 2012
SPARRROW ANNOUNCES NEW APPOINTMENT TO ITS MANAGEMENT TEAM
January 20, 2012
SPARRROW ANNOUNCES NEW APPOINTMENT TO ITS MANAGEMENT TEAM
June 27, 2011
SPARROW ADDRESSES POSTAL STRIKE EFFECTS ON AGM
May 27, 2011
SPARROW ANNOUNCES GRANT OF OPTIONS
April 13, 2011
Sparrow Announces Director Resignation
October 7, 2010
SPARROW VENTURES ANNOUNCES GRANT OF OPTIONS
October 1, 2010
SPARROW APPOINTS RODNEY STEVENS AS SECRETARY
August 31, 2010
SPARROW VENTURES ANNOUNCES GRANT OF OPTIONS
August 26, 2010
SPARROW VENTURES CORP. COMPLETES QUALIFYING TRANSACTION
August 16, 2010
SPARROW VENTURES CORP. FILES FILING STATEMENT REGARDING QUALIFYING TRANSACTION WITH FULL METAL MINERALS LTD.
May 3, 2010
SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT
April 16, 2010
SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT
February 22, 2010
SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT
February 17, 2010
SPARROW VENTURES CORP. ANNOUNCES PROPOSED QUALIFYING TRANSACTION
December 30, 2009
SPARROW CLOSES FINANCING
November 10, 2009
SPARROW ANNOUNCES FINANCING
May 21, 2008
INITIAL PUBLIC OFFERING COMPLETED